

February 3, 2021

To  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai - 400 001

To  
**The National Stock Exchange of India Ltd**  
Exchange Plaza,  
Bandra Kurla Complex, Bandra (E)  
Mumbai - 400 001

**Scrip Code: 524558**

**Scrip Code: NEULANDLAB; Series: EQ**

Dear Sirs,

**Sub: Compliance with Regulation 47(1)(b) of the SEBI Listing Regulations, 2015**



Please find attached herewith copies of the newspaper publication of Un-audited Financial Results for the quarter ended December 31, 2020, published in Financial Express and Andhra Prabha on February 3, 2021 for your reference.

This is for your information and records.

Thanking you,

Yours faithfully,

**For Neuland Laboratories Limited**



**Sarada Bhamidipati**  
Company Secretary

*Encl : As above*

# NEULAND LABORATORIES LIMITED

(CIN : L85195TG1984PLC004393)

Regd. office: Sanali Info park, 'A' Block, Ground floor  
8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034



EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2020

(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	Quarter Ended 31.12.2020	Quarter Ended 31.12.2019	Nine months Ended 31.12.2020	Nine months Ended 31.12.2019
1	Revenue from operations	24,539.18	20,384.37	69,220.84	57,106.89
2	Net profit for the period before tax	3,194.77	1,567.18	8,094.34	3,572.45
3	Net profit for the period after tax	2,673.52	1,111.04	6,333.81	2,550.62
4	Total comprehensive income for the period	2,686.09	1,085.27	6,325.67	2,472.15
5	Paid-up Equity Share Capital (Face value - ₹ 10 each)	1,290.05	1,290.05	1,290.05	1,290.05
6	Earnings Per Share (of ₹ 10 each) (In absolute ₹ terms)				
	(a) Basic	20.84	8.66	49.37	19.88
	(b) Diluted	20.84	8.66	49.37	19.88

Note 1: The financial results for the quarter and nine months ended 31 December 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 2 February 2021.

Note 2: Key Standalone Financial Information:

(Amount in lakhs of ₹)

Particulars	Quarter Ended 31.12.2020	Quarter Ended 31.12.2019	Nine Months Ended 31.12.2020	Nine Months Ended 31.12.2019
Revenue from operations	24,539.18	20,361.97	69,220.84	57,084.49
Net profit for the period before tax	3,185.82	1,557.46	8,064.62	3,541.90
Net profit for the period after tax	2,667.17	1,104.26	6,306.69	2,523.01

Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites, [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and on the Company's website [www.neulandlabs.com](http://www.neulandlabs.com)

By Order of the Board  
For Neuland Laboratories Limited

Dr. D.R.Rao  
Executive Chairman  
(DIN 00107737)

Place: Hyderabad  
Date : 2 February 2021

WEDNESDAY, FEBRUARY 3, 2021

FINANCIAL EXPRESS

# NEULAND LABORATORIES LIMITED

(CIN : L85195TG1984PLC004393)

Regd. office: Sanali Info park, 'A' Block, Ground floor  
8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034



EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2020

(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	Quarter Ended 31.12.2020	Quarter Ended 31.12.2019	Nine months Ended 31.12.2020	Nine months Ended 31.12.2019
1	Revenue from operations	24,539.18	20,384.37	69,220.84	57,106.89
2	Net profit for the period before tax	3,194.77	1,567.18	8,094.34	3,572.45
3	Net profit for the period after tax	2,673.52	1,111.04	6,333.81	2,550.62
4	Total comprehensive income for the period	2,686.09	1,085.27	6,325.67	2,472.15
5	Paid-up Equity Share Capital (Face value - ₹ 10 each)	1,290.05	1,290.05	1,290.05	1,290.05
6	Earnings Per Share (of ₹ 10 each) (In absolute ₹ terms)				
	(a) Basic	20.84	8.66	49.37	19.88
	(b) Diluted	20.84	8.66	49.37	19.88

Note 1: The financial results for the quarter and nine months ended 31 December 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 2 February 2021.

Note 2: Key Standalone Financial Information:

(Amount in lakhs of ₹)

Particulars	Quarter Ended 31.12.2020	Quarter Ended 31.12.2019	Nine Months Ended 31.12.2020	Nine Months Ended 31.12.2019
Revenue from operations	24,539.18	20,361.97	69,220.84	57,084.49
Net profit for the period before tax	3,185.82	1,557.46	8,064.62	3,541.90
Net profit for the period after tax	2,667.17	1,104.26	6,306.69	2,523.01

Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites, [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and on the Company's website [www.neulandlabs.com](http://www.neulandlabs.com)

By Order of the Board  
For Neuland Laboratories Limited

Dr. D.R.Rao  
Executive Chairman  
(DIN 00107737)

Place: Hyderabad  
Date : 2 February 2021